How many drugs treat Tonic-clonic epilepsy?

Drug Landscape tracks 10 marketed treatments for Tonic-clonic epilepsy (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Tonic-clonic epilepsy?

Most recent: Topamax — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/tonic-clonic-epilepsy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tonic-clonic epilepsy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tonic-clonic epilepsy (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tonic-clonic epilepsy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Metabarbital	METHARBITAL	AbbVie	metharbital	GABA-A receptor; anion channel	1982-01-01
Tegretol	carbamazepine	Novartis AG (originally Geigy)	Mood Stabilizer [EPC]	Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	1968-03-11
Peganone	ETHOTOIN	Recordati	Anti-epileptic Agent	Sodium channel alpha subunit	1957-01-01
Mysoline	PRIMIDONE	Bausch Health	Anti-epileptic Agent [EPC]	Transient receptor potential cation channel subfamily M member 3	1954-01-01
Phenytoin Sodium	PHENYTOIN	Viatris	Anti-epileptic Agent	Sodium channel protein type 2 subunit alpha	1953-01-01
Dilantin	Phenytoin Sodium	Pfizer	phenytoin	Nuclear receptor subfamily 1 group I member 3	1953-01-01
Topamax	topiramate	Janssen		Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12
Carbamazepin	Carbamazepin	Enanta Pharmaceuticals, Inc		Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4
Topamax	Topamax	Ataturk University		Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12
phenobarbitone	phenobarbitone	Institute of Child Health		Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-18 — Topamax · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Tonic-clonic epilepsy
AbbVie · 1 drug in Tonic-clonic epilepsy
Ataturk University · 1 drug in Tonic-clonic epilepsy
Bausch Health · 1 drug in Tonic-clonic epilepsy
Enanta Pharmaceuticals, Inc · 1 drug in Tonic-clonic epilepsy
Institute of Child Health · 1 drug in Tonic-clonic epilepsy
Janssen · 1 drug in Tonic-clonic epilepsy
Novartis AG (originally Geigy) · 1 drug in Tonic-clonic epilepsy
Pfizer · 1 drug in Tonic-clonic epilepsy
Recordati · 1 drug in Tonic-clonic epilepsy
Viatris · 1 drug in Tonic-clonic epilepsy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tonic-clonic epilepsy:

Cite this brief

Drug Landscape (2026). Tonic-clonic epilepsy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tonic-clonic-epilepsy. Accessed 2026-06-10.

Tonic-clonic epilepsy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing